The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) first issued a molecular testing guideline in 2013 to recommend testing all patients with advanced lung cancer for TKI-sensitive epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) genomic alterations regardless of clinical characteristics, such as age, race, and smoking status [22]. Here, ALK is linked to lung cancer.